Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus‑associated early stage hepatocellular carcinoma based on RNA‑sequencing data
- Authors:
- Zhili Zeng
- Zebiao Cao
- Ying Tang
-
Affiliations: Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P.R. China, Department of Endocrinology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P.R. China - Published online on: September 11, 2020 https://doi.org/10.3892/ol.2020.12094
- Article Number: 231
-
Copyright: © Zeng et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
|
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A and Roberts LR: A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 16:589–604. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Villanueva A: Hepatocellular carcinoma. N Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yang JD and Roberts LR: Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bruix J and Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases, : Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, et al: Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 29 (Suppl 4):iv238–iv255. 2018. View Article : Google Scholar | |
|
Bruix J and Sherman M; American Association for the Study of Liver Diseases, : Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Varela M, Reig M, de la Mata M, Matilla A, Bustamante J, Pascual S, Turnes J, Aracil C, Del Val A, Pascasio JM, et al: Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers. Med Clin (Barc). 134:569–576. 2010.(In Spanish). View Article : Google Scholar : PubMed/NCBI | |
|
Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, Cicorelli A, Tumino E, Federici G, Cioni R, et al: Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study. Eur J Radiol. 81:1173–1178. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Song YG, Shin SW, Cho SK, Choi D, Rhim H, Lee MW, Kim YS, Park KB, Park HS, Choo SW, et al: Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: A retrospective cohort study of 116 patients. Acta Radiol. 56:70–77. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JW, Kim JH, Sung KB, Ko HK, Shin JH, Kim PN, Choi HK, Ko GY, Yoon HK, Chun SY and Gwon DI: Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller. Am J Gastroenterol. 109:1234–1240. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P and Singal AG: Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 12:870–877. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS, et al: Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol. 110:836–845. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, et al: Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer. 7:235–260. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Takikawa Y and Suzuki K: Is AFP a new reliable marker of liver regeneration in acute hepatic failure? J Gastroenterol. 37:681–682. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Minguez B and Lachenmayer A: Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Markers. 31:181–190. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Gerstein M and Snyder M: RNA-Seq: A revolutionary tool for transcriptomics. Nat Rev Genet. 10:57–63. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, Xing B, Sun W, Ren L, Hu B, et al: Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 567:257–261. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Anders S, Pyl PT and Huber W: HTSeq-a python framework to work with high-throughput sequencing data. Bioinformatics. 31:166–169. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, Kong L, Gao G, Li CY and Wei L: KOBAS 2.0: A web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 39:W316–W322. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al: The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and Lin CY: cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 8 (Suppl 4):S112014. View Article : Google Scholar : PubMed/NCBI | |
|
Bringmann LF, Elmer T, Epskamp S, Krause RW, Schoch D, Wichers M, Wigman JTW and Snippe E: What do centrality measures measure in psychological networks? J Abnorm Psychol. 128:892–903. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI | |
|
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nagy Á, Lánczky A, Menyhárt O and Győrffy B: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 8:92272018. View Article : Google Scholar : PubMed/NCBI | |
|
Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, et al: A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 171:1437–1452 e17. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fu SC, Huang YW, Wang TC, Hu JT, Chen DS and Yang SS: Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: A nationwide cohort study. Aliment Pharmacol Ther. 41:1200–1209. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang YW, Wang TC, Yang SS, Lin SY, Fu SC, Hu JT, Liu CJ, Kao JH and Chen DS: Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: A nation-wide cohort study. Aliment Pharmacol Ther. 42:902–911. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xia H, Chen J, Sekar K, Shi M, Xie T and Hui KM: Clinical and metabolomics analysis of hepatocellular carcinoma patients with diabetes mellitus. Metabolomics. 15:1562019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou QC, Shi B, Jiao LF, Jin M, Sun P, Ding LY and Yuan Y: Hepatopancreas and ovarian transcriptome response to different dietary soybean lecithin levels in portunus trituberculatus. Comp Biochem Physiol Part D Genomics Proteomics. 31:1006002019. View Article : Google Scholar : PubMed/NCBI | |
|
Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, Ohta T and Kaneko S: Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol. 50:100–110. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li N, Li L and Chen Y: The identification of core gene expression signature in hepatocellular carcinoma. Oxid Med Cell Longev. 2018:34783052018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong H, Xiao M, Zarkovic K, Zhu M, Sa R, Lu J, Tao Y, Chen Q, Xia L, Cheng S, et al: Mitochondrial control of apoptosis through modulation of cardiolipin oxidation in hepatocellular carcinoma: A novel link between oxidative stress and cancer. Free Radic Biol Med. 102:67–76. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Zhang C and Feng Z: Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim Biophys Sin (Shanghai). 46:170–179. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rebouissou S and Nault JC: Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 72:215–229. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shao Y, Song X, Jiang W, Chen Y, Ning Z, Gu W and Jiang J: MicroRNA-621 acts as a tumor radiosensitizer by directly targeting SETDB1 in hepatocellular carcinoma. Mol Ther. 27:355–364. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pan YH, Yang M, Liu LP, Wu DC, Li MY and Su SG: UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma. Biochem Biophys Res Commun. 503:895–902. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sun G, Sui X, Han D, Gao J, Liu Y and Zhou L: TRIM59 promotes cell proliferation, migration and invasion in human hepatocellular carcinoma cells. Pharmazie. 72:674–679. 2017.PubMed/NCBI | |
|
Trachootham D, Lu W, Ogasawara MA, Nilsa RD and Huang P: Redox regulation of cell survival. Antioxid Redox Signal. 10:1343–1374. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Oztopcu-Vatan P, Sayitoglu M, Gunindi M and Inan E: Cytotoxic and apoptotic effects of menadione on rat hepatocellular carcinoma cells. Cytotechnology. 67:1003–1009. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu D and Xu Y: p53, oxidative stress, and aging. Antioxid Redox Signal. 15:1669–1678. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
D'Souza LC, Mishra S, Chakraborty A, Shekher A, Sharma A and Gupta SC: Oxidative stress and cancer development: Are noncoding RNAs the missing links? Antioxid Redox Signal. Jan 24–2020.(Epub ahead of print). doi: 10.1089/ars.2019.7987. View Article : Google Scholar | |
|
Maurya AK and Vinayak M: Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line. Mol Biol Rep. 42:1419–1429. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Yang TB, Nan YL, Li AH, Pan DX, Xu Y, Li S, Li T, Zeng XY and Qiu XQ: Genetic variants of cell cycle pathway genes predict disease-free survival of hepatocellular carcinoma. Cancer Med. 6:1512–1522. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E and Los M: Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resist Updat. 10:13–29. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Giono LE and Manfredi JJ: The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol. 209:13–20. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J: The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 6:a0261042016. View Article : Google Scholar : PubMed/NCBI | |
|
Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M and Matsuura N: Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology. 59:68–74. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Gao JZ, Du JL, Huang ZX and Wei LX: Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma. Int J Oncol. 45:1547–1555. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gu J, Liu X, Li J and He Y: MicroRNA-144 inhibits cell proliferation, migration and invasion in human hepatocellular carcinoma by targeting CCNB1. Cancer Cell Int. 19:152019. View Article : Google Scholar : PubMed/NCBI | |
|
Bayard Q, Meunier L, Peneau C, Renault V, Shinde J, Nault JC, Mami I, Couchy G, Amaddeo G, Tubacher E, et al: Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nat Commun. 9:52352018. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y, Li Y, Huang C, Ying L, Xue J, Wu H, Chen Z and Yang Z: Resveratrol enhances HBV replication through activating Sirt1-PGC-1α-PPARα pathway. Sci Rep. 6:247442016. View Article : Google Scholar : PubMed/NCBI | |
|
Huang JY, Chou SF, Lee JW, Chen HL, Chen CM, Tao MH and Shih C: MicroRNA-130a can inhibit hepatitis B virus replication via targeting PGC1α and PPARγ. RNA. 21:385–400. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kanakkanthara A, Jeganathan KB, Limzerwala JF, Baker DJ, Hamada M, Nam HJ, van Deursen WH, Hamada N, Naylor RM, Becker NA, et al: Cyclin A2 is an RNA binding protein that controls Mre11 mRNA translation. Science. 353:1549–1552. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yan H, Li Z, Shen Q, Wang Q, Tian J, Jiang Q and Gao L: Aberrant expression of cell cycle and material metabolism related genes contributes to hepatocellular carcinoma occurrence. Pathol Res Pract. 213:316–321. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lin ZZ, Jeng YM, Hu FC, Pan HW, Tsao HW, Lai PL, Lee PH, Cheng AL and Hsu HC: Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B overexpression in HCC. BMC Cancer. 10:4612010. View Article : Google Scholar : PubMed/NCBI | |
|
Yasen M, Mizushima H, Mogushi K, Obulhasim G, Miyaguchi K, Inoue K, Nakahara I, Ohta T, Aihara A, Tanaka S, et al: Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue. Cancer Sci. 100:472–480. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y and Tanaka H: Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 95:611–619. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wu CX, Wang XQ, Chok SH, Man K, Tsang SHY, Chan ACY, Ma KW, Xia W and Cheung TT: Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics. 8:3737–3750. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuang L, Yang Z and Meng Z: Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in tumor tissues predicted worse overall survival and disease-free survival in hepatocellular carcinoma patients. Biomed Res Int. 2018:78973462018. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang W, Zhang L, Guo Q, Wang H, Ma M, Sun J and Chen C: Identification of the pathogenic biomarkers for hepatocellular carcinoma based on RNA-seq analyses. Pathol Oncol Res. 25:1207–1213. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, Chattopadhyay A, Anantharamaiah GM, Navab M, Fogelman AM, et al: D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. Int J Cancer. 130:1071–1081. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cedó L, García-León A, Baila-Rueda L, Santos D, Grijalva V, Martínez-Cignoni MR, Carbó JM, Metso J, López-Vilaró L, Zorzano A, et al: ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer. Sci Rep. 6:363872016. View Article : Google Scholar : PubMed/NCBI | |
|
Gao F, Vasquez SX, Su F, Roberts S, Shah N, Grijalva V, Imaizumi S, Chattopadhyay A, Ganapathy E, Meriwether D, et al: L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb). 3:479–489. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D, Parsons-Wingerter P, Rayman P, et al: The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem. 288:21237–21252. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Oh C, Park S, Lee EK and Yoo YJ: Downregulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic intervention. Sci Rep. 3:26232013. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Y, Geng Y, Luo J, Shen W, Zhu W, Meng C, Li M, Zhou X, Zhang S and Cao J: Downregulation of ubiquitin inhibits the proliferation and radioresistance of non-small cell lung cancer cells in vitro and in vivo. Sci Rep. 5:94762015. View Article : Google Scholar : PubMed/NCBI | |
|
Tian Y, Ding W, Wang Y, Ji T, Sun S, Mo Q, Chen P, Fang Y, Liu J, Wang B, et al: Ubiquitin B in cervical cancer: Critical for the maintenance of cancer stem-like cell characters. PLoS One. 8:e844572013. View Article : Google Scholar : PubMed/NCBI | |
|
Valdagni R, Rancati T, Ghilotti M, Cozzarini C, Vavassori V, Fellin G, Fiorino C, Girelli G, Barra S, Zaffaroni N, et al: To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 74:1431–1440. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Daniele B, De Vivo R, Perrone F, Lastoria S, Tambaro R, Izzo F, Fiore F, Vallone P and Pignata S: Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis. Anticancer Res. 20:1249–1251. 2000.PubMed/NCBI | |
|
Brandi G, Biasco G, Mirarchi MG, Golfieri R, Di Paolo A, Borghi A, Fanello S, Derenzini E, Agostini V, Giampalma E, et al: A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. Dig Liver Dis. 43:1015–1021. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng CY, et al: Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions. Clin Cancer Res. 24:73–83. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lin HC, Chen YF, Hsu WH, Yang CW, Kao CH and Tsai TF: Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila). 5:952–962. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bhattacharya S, Mondal L, Mukherjee B, Dutta L, Ehsan I, Debnath MC, Gaonkar RH, Pal MM and Majumdar S: Apigenin loaded nanoparticle delayed development of hepatocellular carcinoma in rats. Nanomedicine. 14:1905–1917. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Balamurugan K and Karthikeyan J: Evaluation of luteolin in the prevention of N-nitrosodiethylamine-induced Hepatocellular carcinoma using animal model system. Indian J Clin Biochem. 27:157–163. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chen F, Wang H, Zhu J, Zhao R, Xue P, Zhang Q, Bud Nelson M, Qu W, Feng B and Pi J: Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs. Br J Cancer. 117:1495–1506. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu D, Jin J, Yu H, Zhao Z, Ma D, Zhang C and Jiang H: Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2. J Exp Clin Cancer Res. 36:442017. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao W, Dong W, Zhang C, Saren G, Geng P, Zhao H, Li Q, Zhu J, Li G, Zhang S and Ye M: Effects of the epigenetic drug MS-275 on the release and function of exosome-related immune molecules in hepatocellular carcinoma cells. Eur J Med Res. 18:612013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang B, Yin X and Sui S: Resveratrol inhibited the progression of human hepatocellular carcinoma by inducing autophagy via regulating p53 and the phosphoinositide 3kinase/protein kinase B pathway. Oncol Rep. 40:2758–2765. 2018.PubMed/NCBI | |
|
Park S, Lim J, Kim JR and Cho S: Inhibitory effects of resveratrol on hepatitis B virus X protein-induced hepatocellular carcinoma. J Vet Sci. 18:419–429. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liao PC, Ng LT, Lin LT, Richardson CD, Wang GH and Lin CC: Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells. J Med Food. 13:1415–1423. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Notas G, Nifli AP, Kampa M, Vercauteren J, Kouroumalis E and Castanas E: Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim Biophys Acta. 1760:1657–1666. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bishayee A, Politis T and Darvesh AS: Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev. 36:43–53. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Cheng X, Chen C, Huijuan W, Zhao H, Liu W, Xiang Z and Wang Q: Apigenin, a flavonoid constituent derived from P. villosa, inhibits hepatocellular carcinoma cell growth by CyclinD1/CDK4 regulation via p38 MAPK-p21 signaling. Pathol Res Pract. 216:1527012020. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Z, Zhang H, Cai X, Fang W, Chai D, Wen Y, Chen H, Chu F and Zhang Y: Luteolin promotes cell apoptosis by inducing autophagy in hepatocellular carcinoma. Cell Physiol Biochem. 43:1803–1812. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fan YP, Liao JZ, Lu YQ, Tian DA, Ye F, Zhao PX, Xiang GY, Tang WX and He XX: MiR-375 and doxorubicin Co-delivered by liposomes for combination therapy of hepatocellular carcinoma. Mol Ther Nucleic Acids. 7:181–189. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ang C, O'Reilly EM, Carvajal RD, Capanu M, Gonen M, Doyle L, Ghossein R, Schwartz L, Jacobs G, Ma J, et al: A nonrandomized, phase II study of sequential irinotecan and flavopiridol in patients with advanced hepatocellular carcinoma. Gastrointest Cancer Res. 5:185–189. 2012.PubMed/NCBI | |
|
Liu L, Chen X, Xie S, Zhang C, Qiu Z and Zhu F: Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation. Hepatology. 56:1760–1769. 2012. View Article : Google Scholar : PubMed/NCBI |
